1.Tratamiento localizado del cáncer de próstata. http://www.hifu-planet.com/4_Espanol/accueil.html 2.Carballido JA, Alvarez-Mon M. Patología prostática. Programa educacional Urología.1997; Unidad temática 2:6-16 3.Hernández C, Jara J, Durán R. Monografía de actualización en patología prostática. Editores Médicos; 1995: 15-28. 4.Santana L y Wong H. criterios actuales para evaluar la conducta a seguir con los pacientes que padecen de hiperplasia prostática benigna. Rev Cubana Cir 2004: 43:1. 5.Shander A: Bioética en el tratamiento de los pacientes Testigos de Jehová. En: Cardemil G (ed). Alternativas del uso de sangre y sus derivados. Rev. Hosp. Univ de Chile 2000; 11: 387 – 91Mollison PL Blood transfusion in clinical medicine. 4th ed. Philadelphia: FA Davis, 1967. 6.Vilchez E: Consentimiento informado y transfusiones de sangre. En: Cardemil G (ed). Alternativas del uso de sangre y sus derivados. Rev. Hosp. Univ de Chile 2000; 11: 287 – 90 7.Schmunis GA, Zicker F, Blandling BD: Risk for transfusion-transmitted infections in central and South America. Emerg infect Dis 1998; 4: 5-11. 8.Shander A: Manejo del paciente en cuidados intensivos. En: Cardemil G (ed). Alternativas al uso de la sangre y Derivados. Rev Hosp. Clin Univ de Chile 2000; 11: 363-70 9.Graves Cl, Allen RM Anesthesia in the presence of anemia severe. Rocky Mt Med J 1970; 67:35-40 10.Rawstron RE, Anaemia and surgery: a retrospective clinical study. Aust NZ Surg 1970; 39:425-32 11.Algora M, Fernández A, Gómez JL, Martín C, Prats I, Puig N, et al. Guía sobre la indicación de la transfusión de glóbulos rojos, plaquetas y productos plasmáticos lábiles. Med Clin (Barc) 1999; 113: 471-474. 12.Toy PT. Audit and education in transfusion medicine. Vox Sang 1996; 70: 1- 5. 13.Rubin GL, Schofield WN, Dean MG, Shakeshaft AP. Appropriateness of red blood cell transfusions in major urban hospitals and effectiveness of an intervention. Med J Aust 2001; 175: 354-358. 14.Wilson K, MacDougall L, Fergusson D, Graham I, Tinmouth A, Hébert PC. The effectiveness of interventions to reduce physician’s levels of inappropriate transfusion: what can be learned from a systematic review of the literature. Transfusion 2002; 42: 1224-1229. 15.Llau JV, García Pérez ML. Tratado de hemostasia y medicina transfusional perioperatoria. Rev. Esp. Anestesiol Reanim 2001; 48: 103-105 16.Rama P, Acción M, González M, Fernández B, Diéguez M, López I. Necesidades transfusionales durante el intra y postoperatorio inmediato de la artroplastia de cadera y rodilla. Incidencia y factores asociados. Rev Esp Anestesiol Reanim 1999;46: 445-452. 17.Stanworth SJ, Cockburn HA, Boralessa H, Contreras M. Which groups of patients are transfused? A study of red cell usage in London and southeast England. Vox Sang 2002; 83: 352-357. 18.Conseiller C, Ozier Y, Rosencher N. Compensación de las pérdidas de glóbulos rojos en cirugía. Encicl Med Quirur. Ed española. 1999. E- 36-735-B-10. 19.Drouet N. Pour le groupe de travail SANGUIS. Les pratiques transfusionnelles européennes: l’enquête SANGUIS. Cahiers Anesth 1994; 42: 425-428. 20.Larrondo M: Control de infecciones intrahospitalaria. En: Fica A, Ruiz G (eds). Productos farmacológicos y normas transfusionales. Rev Hosp. Clin Univ de Chile 2000; 101-12. 21.Stehling L. Autologous transfusión. Miller R, editor. Anaesthesia 4 edición. 1994; 51: 1647-60. 22.Schmunis GA, Zicker F, Blandling BD: Risk for transfusion-transmitted infections in central and South America. Emerg infect Dis 1998; 4: 11-14. 23.Llau JV, Díaz A, et al. Reducción de las necesidades transfusionales con aprotinina en cirugía ortopédica. Rev Esp Anestesiol Reanim 2000; 47: 309-16. 24.García Caballero M. Medidas farmacológicas de ahorro de sangre en cirugía. Cirugía Española 2001; 69 (2): 146-58. 25.Freischlag JA. Intraoperative blood salvages in vascular surgery-worth the effort? Critical Care 2004; 8 (Supl. 2): S53-S56Cohn S: Uso de la sangre en el siglo XXI. En: Cardemil G (ed). Alternativas al uso de la sangre y Derivados. Rev Hosp. Clin Univ de Chile 2000; 11: 409-13. 26.Lundy JS: Clinical anestesia. Philadelfia: W.B. Saunders, 1942 27.Herederos de O Redondo: Juzgando el crimen de Quillota. Rol, 44941-3, enero 2002 28.Hospital San José/Ángela Díaz C: Resolución 128538. Rol 2496-02, agosto, 2002 29.Giuseppe R, Luigi M. Hematologic Consequences of Renal Failure. Brenner and Rector’s. The Kidney, Sixth Edition 2000; 2079-2102.Shander A: Hipovolemia y reemplazo de volumen. En: Cardemil G (ed). Alternativas al uso de la sangre y Derivados. Rev Hosp. Clin Univ de Chile 2000; 11: 379-86. 30.Miyake T, Kung CK-H, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558-5564. 31.Koury ST, Bondurat MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridisation. Blood 1988; 71:524-7. 32.Juul SE, Stallings SA, Christensen RD. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatric Res 1999; 46: 543 547. 33.Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, Sasaki R. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994; 269: 19488 19493. 34.Eschbach JW, Nelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158-163. 35.Goodnough LT, Monk TG, Andriole GL. Current concepts: erythropoietin theraphy. N Engl J Med 1997; 336: 933-938. 36.Allegro A, Galasso A, Siracusano L, Aloisi C, Corica F, Lagana A et al. Administration of recombinant erythropoietin determines increase of peripheral resistances in patients with hypovolemic shock. Nephron 1996; 74: 431-432. 37.Buemi M, Denuzzo G, Allegra A, Aloisi C, Squadrito F, Squadrito G et al. Recombinant human erythropoietin inhibits the cutaneous vasodilatation induced by acetyl-choline. Int J Microcirc 1995; 15: 283-286. 38.Buemi M, Allegra A, Aloisi C, Frisina N. Influence of therapy with recombinant erythropoietin on serum levels of neopterin in hemodialyzed subjects. Am J Nephrol 1991; 11: 281-283. 39.Kokot F, Wiecek A, Grzesczak W, Klepacka J, Klin M, Lao M. Influence of erythropoietin treatment on endocrine abnormalities in hemodialyzed patients. Contrib Nephrol 1989; 76: 257-270. 40.Goodnouh LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 336:933-8 41.Morera. 42.Feagan BG, Wong CJ, Kirkley A, johnston DW, Smith FC, Whitsitt P, et al. Erythropoietin with iron supplementation to prevent allogenic blood transfusion in total hip joint arthroplasty. A randomised, controlled trial. Ann Inter Med 2000; 133:845-54. 43.Nieder AM, Rosenblum n, Lepor H. Comparison of two different doses preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. Urology 2001; 57:737-41. 44.“EPREX” Product Monograph 2005. Disponible en: http://www.janssen-ortho.com/JOI/pdf_files/Eprex_E.pdf. 45.Rev. Esp. Anestesiol. Reanim. 2003; 50: 395-400. 46.Goldberg Ma et al Am J of Orthoped 1996; 25: 533-542 47.Goldberg MA, McCutchen JW, Jove M, Di Cesare P, Friedman RJ, Poss R et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop 1996; 25: 544-552. [Medline] 48.Stowell CP, Chandler H, Jove M, Guilfoyle M, Wacholtz MC. An open-label, ramdomized study to compare the safety and efficacy of perioperative epoetin alfa with preoperative autologous blood donation in total joint arthroplasty. Orthopedics 1999; 22 (Supl 1): 105-112. 49.Pérez-Oliva JF, Lagarde AM, Herrera R. Eficacia del tratamiento con eritropoyetina recombinante humana cubana (epocim), en pacientes anémicos hemodializados. Rev Hab C Médicas 2004; 3 (10): 5-10. 50.Pérez-Oliva JF, Lagarde AM, Herrera R, Martínez AI, Raola ME, Magrans Ch. Broad Use of Cuban Recombinant Human Erythropoietin (ior-EPOCIM) in Dialysis Patients at the Institute of Nephrology. Medic Review 2005; VII (5). Disponible en: http://www.medicc.org/medicc_review/0505/cuban-medical-literature-2.html 51.Tryba M. Epoetin alfa plus autologous blood donation in patients with low hematocrit scheduled to undergo orthopedic surgery. Sem Hematol 1997; 33 (Supl 2): 22-24. 52.Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; ii: 1175-1178. 53.“PROCRIT”. Product Monograph 2005. Disponible en: http://www.procrit.com. 54.Jacquot C, Ferragu-Haguet M, Lefebvre A, Berthelot JM, Peterlongo F, Castiagne JP. Recombinant erythropoietin and blood pressure (Letter to the editor). Lancet 1987; ii: 1083. 55.Dessypris EN, Kranstz SB. Effect of pure erythropoietin on DNA synthesis by human marrow day 15 erythroid burst forming units in short-term liquid culture. Br J Haematol 1984; 56:295-306. 56.Rober G. Chronic renal failure. Goldman; Cecil textbook of medicine, 21st ed. 2000; 571-706. 57.Llach F, Valderrábano F. Insuficiencia renal crónica. Diálisis y trasplante renal. Vol 1. La Habana: Editorial Ciencias Médicas; 1997. 58.Knoyan GE, Levin N, Eschbach J, Golper T, Kopple J, Owen W. Clinical practice guide for the treatment of anemic of chronic renal failure DOQI. New York: National Kidney Foundation; 1997. 59.Nssen- Cilag JA. Norma Europea para tratamiento de anemia doscientos con insuficiencia renal crónica. Rev Portug Nefrol Hiperten 1999; 13(3): 33-58 60.Goodnough LT. The case against universal leukoreduction (and for the practice of evidence-based medicine). Transfusion 2000; 40: 1522-27. 61.De Andrade JR, Frei D, Guilfoyle M.. Integrated analysis of thrombotic/vascular events occurrence in epoetin alfa treated patients undergoing major, elective orthopedic surgery. Orthopedics 1999; 22 (Supl 1): 113-118. 62.CazenaveJP, Irrmann C, Wallen C, Sondag D, Beudoux E, Genetel B et al. Epoetin alfa facilitates presurgical autologous blood donation in non-anemic patients scheduled for orthopaedic or cardiovascular surgery. Eur J Anesthesiol 1997; 14: 432-442. 63.Anders MJ, Lifeso RM, Landis M, Mikulsky J, Meinking C, McCracken K. Effect of preoperative donation of autologous blood on deep-vein thrombosis following total joint arthroplasty of the hip or knee. J Bone Joint Surg 1996; 78 (Supl A): 574-580. 64.Goya N, Toda F, Nishino S, Tokumoto T, Iguchi Y, Kobayashi H et al. Autotransfusion supported by erythropoietin therapy in transurethral resection of the prostate. Scand J Urol Nephrol 1998; 32: 383-387. 65.Erikssen G, Thaulow E, SandvikL, Stormorken H, Erikssen J.. Haematocrit: a predictor of cardiovascular mortality? J Intern Med 1993; 234: 493-499. 66.Sowade B, Sowade O, Mocks J, Franke W, Warnke H. The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. Int J Mol Med 1998 Feb;1(2):303-14. 67.López J, Piera RL. Efecto beneficioso del tratamiento con Eritropoyetina Humana Recombinante. Fernando Valderrábano. España: Biblio STN. MASSON 1998; 119-179. 68.Bisbe, M. Sáez, N. Nomen, J. Castillo, X. Santiveri, C. Mestre, X. Cano. Eritropoyetina sola o como coadyuvante del programa de donación de sangre autóloga en cirugía ortopédica mayor. Rev. Esp. Anestesiol. Reanim. 2003; 50: 395-400.
Versión para impresión